Pembrolizumab in Programmed Death Ligand 1-Positive Endometrial Cancer
- PMID: 28880747
- DOI: 10.1200/JCO.2017.74.4987
Pembrolizumab in Programmed Death Ligand 1-Positive Endometrial Cancer
Comment in
-
Reply to F. Tomao et al.J Clin Oncol. 2017 Nov 1;35(31):3633-3634. doi: 10.1200/JCO.2017.74.8681. Epub 2017 Sep 7. J Clin Oncol. 2017. PMID: 28880745 No abstract available.
Comment on
-
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489510 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
